Effect of small interfering RNA 3'-end overhangs on chemosensitivity to thymidylate synthase inhibitors

Silence

Volumn 2, Issue 1, 2011, Pages

  Schmitz, John C ^a,b   Chu, Edward ^b  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLOXURIDINE DERIVATIVE; POLYETHYLENEIMINE; RALTITREXED; SMALL INTERFERING RNA; THYMIDINE; THYMIDYLATE SYNTHASE; THYMIDYLATE SYNTHASE INHIBITOR; URIDINE;

ARTICLE; CANCER CELL; CELL GROWTH; CELL PROLIFERATION; CHEMOSENSITIVITY; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; DNA SYNTHESIS INHIBITION; DRUG ACTIVITY; GENE EXPRESSION PROFILING; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; PROTEIN TARGETING; RNA DEGRADATION; TISSUE SPECIFICITY;

EID: 84857791418     PISSN: None     EISSN: 1758907X     Source Type: Journal    
DOI: 10.1186/1758-907X-2-1     Document Type: Article

References (32)

1. Carreras CW, Santi DV. The catalytic mechanism and structure of thymidylate synthase. Annu Rev Biochem 1995, 64:721-762. 10.1146/annurev.bi.64.070195.003445, 7574499.
2. Danenberg PV. Thymidylate synthetase - a target enzyme in cancer chemotherapy. Biochim Biophys Acta 1977, 473:73-92.
3. Hardy LW, Finer-Moore JS, Montfort WR, Jones MO, Santi DV, Stroud RM. Atomic structure of thymidylate synthase: target for rational drug design. Science 1987, 235:448-455. 10.1126/science.3099389, 3099389.
4. Schmitz JC, Chen TM, Chu E. Small interfering double-stranded RNAs as therapeutic molecules to restore chemosensitivity to thymidylate synthase inhibitor compounds. Cancer Res 2004, 64:1431-1435. 10.1158/0008-5472.CAN-03-1203, 14973067.
5. Yadava P, Roura D, Hughes JA. Evaluation of two cationic delivery systems for siRNA. Oligonucleotides 2007, 17:213-222. 10.1089/oli.2006.0062, 17638525.
6. Podesta JE, Al-Jamal KT, Herrero MA, Tian B, Ali-Boucetta H, Hegde V, Bianco A, Prato M, Kostarelos K. Antitumor activity and prolonged survival by carbon-nanotube-mediated therapeutic siRNA silencing in a human lung xenograft model. Small 2009, 5:1176-1185. 10.1002/smll.200990047, 19306454.
7. Woodrow KA, Cu Y, Booth CJ, Saucier-Sawyer JK, Wood MJ, Saltzman WM. Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA. Nat Mater 2009, 8:526-533. 10.1038/nmat2444, 2693358, 19404239.
8. Urban-Klein B, Werth S, Abuharbeid S, Czubayko F, Aigner A. RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther 2005, 12:461-466. 10.1038/sj.gt.3302425, 15616603.
9. Ofek P, Fischer W, Calderon M, Haag R, Satchi-Fainaro R. In vivo delivery of small interfering RNA to tumors and their vasculature by novel dendritic nanocarriers. FASEB J 2010, 24:3122-3134. 10.1096/fj.09-149641, 20385622.
10. Xia T, Kovochich M, Liong M, Meng H, Kabehie S, George S, Zink JI, Nel AE. Polyethyleneimine coating enhances the cellular uptake of mesoporous silica nanoparticles and allows safe delivery of siRNA and DNA constructs. ACS Nano 2009, 3:3273-3286. 10.1021/nn900918w, 19739605.
11. Lee JS, Green JJ, Love KT, Sunshine J, Langer R, Anderson DG. Gold, poly(beta-amino ester) nanoparticles for small interfering RNA delivery. Nano Lett 2009, 9:2402-2406. 10.1021/nl9009793, 2728206, 19422265.
12. Kleemann E, Neu M, Jekel N, Fink L, Schmehl T, Gessler T, Seeger W, Kissel T. Nano-carriers for DNA delivery to the lung based upon a TAT-derived peptide covalently coupled to PEG-PEI. J Control Release 2005, 109:299-316. 10.1016/j.jconrel.2005.09.036, 16298009.
13. Bolcato-Bellemin AL, Bonnet ME, Creusat G, Erbacher P, Behr JP. Sticky overhangs enhance siRNA-mediated gene silencing. Proc Natl Acad Sci USA 2007, 104:16050-16055. 10.1073/pnas.0707831104, 2042160, 17913877.
14. Dokka S, Malanga CJ, Shi X, Chen F, Castranova V, Rojanasakul Y. Inhibition of endotoxin-induced lung inflammation by interleukin-10 gene transfer in mice. Am J Physiol Lung Cell Mol Physiol 2000, 279:L872-877.
15. Fedorov Y, King A, Anderson E, Karpilow J, Ilsley D, Marshall W, Khvorova A. Different delivery methods-different expression profiles. Nat Methods 2005, 2:241. 10.1038/nmeth0405-241, 15782213.
16. Ma Z, Li J, He F, Wilson A, Pitt B, Li S. Cationic lipids enhance siRNA-mediated interferon response in mice. Biochem Biophys Res Commun 2005, 330:755-759. 10.1016/j.bbrc.2005.03.041, 15809061.
17. Nolte A, Raabe C, Walker T, Simon P, Ziemer G, Wendel HP. Optimized basic conditions are essential for successful siRNA transfection into primary endothelial cells. Oligonucleotides 2009, 19:141-150. 10.1089/oli.2009.0182, 19441891.
18. Yang Z, Cloud A, Hughes D, Johnson LF. Stable inhibition of human thymidylate synthase expression following retroviral introduction of an siRNA gene. Cancer Gene Ther 2006, 13:107-114. 10.1038/sj.cgt.7700880, 16052228.
19. Smith SG, Lehman NL, Moran RG. Cytotoxicity of antifolate inhibitors of thymidylate and purine synthesis to WiDr colonic carcinoma cells. Cancer Res 1993, 53:5697-5706.
20. Yin MB, Guimaraes MA, Zhang ZG, Arredondo MA, Rustum YM. Time dependence of DNA lesions and growth inhibition by ICI D1694, a new quinazoline antifolate thymidylate synthase inhibitor. Cancer Res 1992, 52:5900-5905.
21. DeVincenzo J, Lambkin-Williams R, Wilkinson T, Cehelsky J, Nochur S, Walsh E, Meyers R, Gollob J, Vaishnaw A. A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc Natl Acad Sci USA 107:8800-8805. 10.1073/pnas.0912186107, 2889365, 20421463.
22. Kim HP, Yoon YK, Kim JW, Han SW, Hur HS, Park J, Lee JH, Oh DY, Im SA, Bang YJ, Kim TY. Lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, downregulates thymidylate synthase by inhibiting the nuclear translocation of EGFR and HER2. PLoS One 2009, 4:e5933. 10.1371/journal.pone.0005933, 2691960, 19529774.
23. Liu G, Hu X, Chakrabarty S. Vitamin D mediates its action in human colon carcinoma cells in a calcium-sensing receptor-dependent manner: downregulates malignant cell behavior and the expression of thymidylate synthase and survivin and promotes cellular sensitivity to 5-FU. Int J Cancer 2010, 126:631-639. 10.1002/ijc.24762, 19621386.
24. DeGregori J, Kowalik T, Nevins JR. Cellular targets for activation by the E2F1 transcription factor include DNA synthesis- and G1/S-regulatory genes. Mol Cell Biol 1995, 15:4215-4224. 230660, 7623816.
25. Powell CM, Rudge TL, Zhu Q, Johnson LF, Hansen U. Inhibition of the mammalian transcription factor LSF induces S-phase-dependent apoptosis by downregulating thymidylate synthase expression. EMBO J 2000, 19:4665-4675. 10.1093/emboj/19.17.4665, 302058, 10970859.
26. Yoo BK, Gredler R, Vozhilla N, Su ZZ, Chen D, Forcier T, Shah K, Saxena U, Hansen U, Fisher PB, Sarkar D. Identification of genes conferring resistance to 5-fluorouracil. Proc Natl Acad Sci USA 2009, 106:12938-12943. 10.1073/pnas.0901451106, 2722317, 19622726.
27. Le Francois BG, Maroun JA, Birnboim HC. Expression of thymidylate synthase in human cells is an early G(1) event regulated by CDK4 and p16INK4A but not E2F. Br J Cancer 2007, 97:1242-1250. 10.1038/sj.bjc.6604020, 2360461, 17923872.
28. Lee JH, Park JH, Jung Y, Kim JH, Jong HS, Kim TY, Bang YJ. Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells. Mol Cancer Ther 2006, 5:3085-3095. 10.1158/1535-7163.MCT-06-0419, 17172411.
29. Mannava S, Grachtchouk V, Wheeler LJ, Im M, Zhuang D, Slavina EG, Mathews CK, Shewach DS, Nikiforov MA. Direct role of nucleotide metabolism in C-MYC-dependent proliferation of melanoma cells. Cell Cycle 2008, 7:2392-2400.
30. Fakih MG, Pendyala L, Fetterly G, Toth K, Zwiebel JA, Espinoza-Delgado I, Litwin A, Rustum YM, Ross ME, Holleran JL, Egorin MJ. A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer. Clin Cancer Res 2009, 15:3189-3195. 10.1158/1078-0432.CCR-08-2999, 19383814.
31. Jackson AL, Burchard J, Leake D, Reynolds A, Schelter J, Guo J, Johnson JM, Lim L, Karpilow J, Nichols K, Marshall W, Khvorova A, Linsley PS. Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. RNA 2006, 12:1197-1205. 10.1261/rna.30706, 1484422, 16682562.
32. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227:680-685. 10.1038/227680a0, 5432063.